Exacerbation of Secondary Cold Agglutinin Syndrome in the Setting of SARS-CoV-2

Abstract

In this report, we present a case of exacerbation of cold agglutinin syndrome (CAS) potentially due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. An 83-year-old female with a history of cold agglutinin hemolytic anemia presented with shortness of breath, productive cough, worsening orthopnea, darkening fingers and urine, and jaundice. Laboratory investigations found elevated white blood cells (WBC) and total bilirubin, severely low hemoglobin, and positive direct Coombs test. Moreover, SARS-CoV-2 RNA was also found to be positive in a sample from the nasal swab by reverse transcription-polymerase chain reaction (RT-PCR), indicating exacerbation of CAS secondary to viral coronavirus 2019 (COVID-19) infection. A treatment regime for SARS-CoV-2 consisting of five days of remdesivir and seven days of dexamethasone 6 mg IV was initiated, resulting in significant improvement in the patient's condition.

Cold Agglutinin Disease and COVID-19: A Scoping Review of Treatments and Outcomes

“…Characteristics of included studies are reported in Table 1 [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. All the studies were case reports (17/19) Examples of comorbidities included hypertension, type 2 diabetes mellitus, end-stage renal disease, cirrhosis, chronic obstructive airway disease, chronic lymphocytic leukemia, etc.…”